Loading...
•
Sep 30, 2022
CVS Health Q3 2022 Earnings Report
CVS Health's financial performance was impacted by opioid litigation charges and a loss on assets held for sale, but adjusted EPS still increased.
Key Takeaways
CVS Health reported a revenue increase of 10.0% to $81.2 billion. However, the company experienced a GAAP loss per share of $(2.60) due to significant charges, including $5.2 billion for opioid litigation and $2.5 billion related to the Omnicare long-term care business. Despite the loss, the adjusted EPS was $2.09.
Total revenues increased to $81.2 billion, up 10.0% compared to prior year.
GAAP loss per share of $(2.60), inclusive of $5.2 billion pre-tax opioid litigation charges and a $2.5 billion pre-tax loss on assets held for sale related to the Omnicare® long-term care business.
Adjusted EPS of $2.09.
The company entered into a definitive agreement to acquire Signify Health, Inc. for $30.50 per share in cash.
CVS Health
CVS Health
CVS Health Revenue by Segment
Revenue by Segment
Health Care Benefits Revenue
CapyFin.comHealth Services Revenue
CapyFin.comPharmacy & Consumer Wellness Revenue
CapyFin.com Forward Guidance
CVS Health revised its full-year 2022 GAAP diluted EPS guidance range to $3.12 to $3.22 from $7.23 to $7.43 and raised its full-year 2022 Adjusted EPS guidance range to $8.55 to $8.65 from $8.40 to $8.60. The Company also raised its full-year 2022 cash flow from operations guidance range to $13.5 billion to $14.5 billion from $12.5 billion to $13.5 billion.
Positive Outlook
- Raised Adjusted EPS guidance range to $8.55 to $8.65 from $8.40 to $8.60
- Raised cash flow from operations guidance range to $13.5 billion to $14.5 billion from $12.5 billion to $13.5 billion
- The adjustments between full-year 2022 GAAP diluted EPS and Adjusted EPS include amortization of intangible assets
- The adjustments between full-year 2022 GAAP diluted EPS and Adjusted EPS include opioid litigation charges
- The adjustments between full-year 2022 GAAP diluted EPS and Adjusted EPS include losses on assets held for sale
Challenges Ahead
- Revised GAAP diluted EPS guidance range to $3.12 to $3.22 from $7.23 to $7.43
- Forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties
- Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties related to the COVID-19 pandemic
- The risk that the acquisition may not close in the anticipated timeframe or at all due to one or more of the other closing conditions to the transaction not being satisfied or waived
- The risk that any announcements relating to the proposed transaction could have adverse effects on the market price of CVS Health’s common stock, credit ratings or operating results
Revenue & Expenses
Visualization of income flow from segment revenue to net income